Alprostadil: Molecular Structure

Molecular Structure and Properties#

Alprostadil is prostaglandin E1 (PGE1), a naturally occurring 20-carbon oxygenated fatty acid belonging to the prostanoid family of lipid mediators. It is not a peptide and contains no amino acid residues. Its molecular formula is C20H34O5, with a molecular weight of 354.48 g/mol and CAS registry number 745-65-3. Alprostadil is one of the primary prostaglandins produced endogenously from dihomo-gamma-linolenic acid (DGLA, 20:3 n-6) through the cyclooxygenase (COX) pathway, and it serves as a potent vasodilator and inhibitor of platelet aggregation.

Classification and Chemical Identity#

Alprostadil belongs to the E-series prostaglandins, which are defined by the presence of a ketone group at the C-9 position and a hydroxyl group at the C-11 position of the cyclopentane ring. Prostaglandins as a class are eicosanoids -- signaling molecules derived from 20-carbon polyunsaturated fatty acids. Unlike peptide therapeutics that are composed of amino acid chains linked by peptide bonds, alprostadil is a lipid-derived compound with an entirely different chemical scaffold: a cyclopentane ring system with two aliphatic side chains bearing specific functional groups.

The IUPAC name for alprostadil is (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. It is also referred to as PGE1, prostaglandin E1, or by various trade names including Caverject, Edex, MUSE, and Prostin VR Pediatric.

Prostanoid Structural Features#

The structural architecture of alprostadil is organized around a central cyclopentane ring with two substituent chains:

Cyclopentane ring (C-8 through C-12):

• C-9 position: ketone group (=O), the defining feature of E-series prostaglandins
• C-11 position: alpha-hydroxyl group (-OH), oriented below the plane of the ring
• The ring provides the rigid core scaffold that positions the functional groups for receptor recognition

Alpha chain (C-1 through C-7):

• A seven-carbon carboxylic acid chain extending from C-8 of the ring
• The terminal carboxylic acid group at C-1 is critical for receptor binding and is ionized at physiological pH
• This chain adopts a largely extended conformation

Omega chain (C-13 through C-20):

• An eight-carbon aliphatic chain extending from C-12 of the ring
• C-13 to C-14: trans (E) double bond, introducing a degree of rigidity in the omega chain
• C-15 position: S-configured hydroxyl group (-OH), essential for biological activity
• The terminal portion (C-16 through C-20) is a saturated hydrocarbon tail

The trans double bond between C-13 and C-14 is a distinguishing structural element that differentiates PGE1 from other prostaglandin E-series members. PGE2, for comparison, contains an additional cis double bond between C-5 and C-6 in the alpha chain, reflecting its biosynthesis from arachidonic acid (20:4 n-6) rather than DGLA (20:3 n-6).

Biosynthesis from Dihomo-gamma-linolenic Acid#

Endogenous alprostadil is synthesized from dihomo-gamma-linolenic acid (DGLA; 20:3 n-6) through the cyclooxygenase pathway:

1. Substrate liberation: DGLA is released from membrane phospholipids by the action of phospholipase A2 (PLA2), which cleaves the sn-2 ester bond of glycerophospholipids.

2. Cyclooxygenase reaction: COX-1 or COX-2 catalyzes the bis-dioxygenation and cyclization of DGLA. The enzyme first abstracts the pro-S hydrogen at C-13, generating a carbon-centered radical that undergoes two sequential oxygenation steps and ring closure to form the cyclic endoperoxide intermediate PGG1.

3. Peroxidase reduction: The 15-hydroperoxide of PGG1 is reduced to the 15-hydroxyl group by the peroxidase activity of the same COX enzyme, yielding PGH1.

4. Isomerase conversion: PGE synthase (mPGES-1, mPGES-2, or cPGES) catalyzes the isomerization of PGH1 to PGE1 (alprostadil) by opening the cyclic endoperoxide and forming the C-9 ketone and C-11 hydroxyl.

The pharmaceutical product is produced by total chemical synthesis rather than biosynthetic extraction, ensuring high purity and stereochemical control.

Physical and Chemical Properties#

Stability and Degradation#

Alprostadil is chemically unstable under several conditions, which has significant implications for pharmaceutical formulation and handling:

Oxidative degradation: The allylic hydroxyl at C-15 and the bis-allylic system are susceptible to autoxidation. Exposure to atmospheric oxygen generates hydroperoxide and epoxide degradation products. Antioxidants such as alpha-tocopherol or butylated hydroxytoluene (BHT) may be incorporated into formulations to mitigate this pathway.

Thermal degradation: Elevated temperatures accelerate both oxidative and epimerization reactions. The C-15 hydroxyl group can undergo epimerization from the bioactive (15S) to the inactive (15R) configuration. Storage at controlled room temperature (20-25 degrees C) or refrigeration (2-8 degrees C) is required depending on the formulation.

Photodegradation: UV and visible light promote radical-mediated degradation pathways. Pharmaceutical packaging uses amber or light-protective containers.

pH-dependent hydrolysis: In strongly acidic or basic conditions, the cyclopentanone ring can undergo ring-opening or the ester/acid functionalities can be affected. The molecule is most stable at mildly acidic to neutral pH (4.0-7.0).

Dehydration: Under acidic conditions, loss of water from the C-11 hydroxyl can yield PGA1 (prostaglandin A1), an alpha,beta-unsaturated ketone. This dehydration product has different biological activity and represents a significant degradation concern.

Pharmaceutical formulations of alprostadil address these stability challenges through lyophilization (Caverject), use of alpha-cyclodextrin inclusion complexes (Edex/Viridal), or formulation in polyethylene glycol-based suppositories (MUSE). The Caverject dual-chamber system separates the lyophilized alprostadil powder from the reconstitution diluent until the point of use.

Pharmacokinetics#

Alprostadil is characterized by extremely rapid metabolism, which profoundly shapes its pharmacokinetic profile and routes of administration.

Absorption and Administration Routes#

• Intravenous (Prostin VR Pediatric): Direct systemic delivery for neonatal patent ductus arteriosus (PDA) management. Continuous infusion is required due to the extremely short half-life.
• Intracavernosal injection (Caverject/Edex): Injection directly into the corpus cavernosum provides high local drug concentrations at the target tissue. Systemic absorption is relatively limited due to local metabolism and the venous drainage occlusion that occurs during erection.
• Intraurethral (MUSE): A pellet of alprostadil is inserted into the urethra, where the drug is absorbed through the urethral mucosa into the surrounding corpus spongiosum and subsequently into the corpora cavernosa via vascular communications. Bioavailability is approximately 7-9% of the intraurethral dose.

Distribution#

Following intravenous administration, alprostadil distributes rapidly throughout the body. Plasma protein binding is approximately 81%, primarily to albumin. The apparent volume of distribution has not been precisely characterized in humans due to the extremely rapid metabolism, but is estimated to be approximately 0.1-0.2 L/kg, suggesting distribution is largely confined to the vascular compartment and well-perfused tissues.

Metabolism#

Metabolism of alprostadil is extraordinarily rapid and occurs primarily through three enzymatic steps:

1. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH): This is the primary and rate-limiting catabolic enzyme. It oxidizes the 15(S)-hydroxyl group to a 15-keto group, producing 15-keto-PGE1. This enzyme is present at high concentrations in the pulmonary vasculature, which accounts for the remarkable first-pass pulmonary metabolism. Approximately 80% of circulating alprostadil is metabolized in a single pass through the lungs.

2. Delta-13-reductase (prostaglandin delta-reductase): This enzyme reduces the C-13 trans double bond, yielding 13,14-dihydro-15-keto-PGE1, the principal circulating metabolite.

3. Beta-oxidation and omega-oxidation: The metabolites undergo further chain shortening through hepatic beta-oxidation (similar to fatty acid catabolism) and omega-oxidation, producing dinor and tetranor metabolites that are excreted renally.

The combination of rapid pulmonary and hepatic metabolism results in nearly complete clearance from the systemic circulation within minutes.

Elimination#

• Intravenous half-life: Approximately 30 seconds to 1 minute for the parent compound in the systemic circulation. Some sources report a distribution half-life (alpha) of approximately 30 seconds and an elimination half-life (beta) of approximately 5-10 minutes, reflecting the biphasic disappearance from plasma.
• Clearance: Total body clearance is extremely high, approximately 7,000-9,000 mL/min, exceeding cardiac output and confirming extensive extrahepatic (primarily pulmonary) metabolism.
• Excretion: Metabolites are excreted primarily in urine (~88% within 24 hours) and to a lesser extent in feces (~12%). Virtually no intact alprostadil is recovered in urine.

Pharmacokinetic Implications#

The rapid metabolism of alprostadil has several practical consequences:

• Intravenous administration requires continuous infusion to maintain therapeutic plasma concentrations.
• Intracavernosal injection capitalizes on local tissue effects before systemic metabolism occurs; only about 2-5% of an intracavernosal dose reaches the systemic circulation as intact drug.
• The short systemic half-life provides a built-in safety mechanism: cessation of infusion leads to rapid decline in systemic effects, reducing the risk of prolonged hypotension.
• Oral bioavailability is effectively zero due to gastrointestinal degradation and complete first-pass metabolism; no oral formulation exists.

Mechanism of Action#

Alprostadil exerts its pharmacological effects primarily through activation of E-type prostanoid (EP) receptors, particularly EP2 and EP4 subtypes, which are Gs-protein-coupled receptors:

1. Receptor binding: Alprostadil binds to EP2 and EP4 receptors on vascular smooth muscle cells, platelets, and other target cells.
2. Adenylate cyclase activation: The Gs-alpha subunit stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP).
3. Protein kinase A activation: Elevated cAMP activates protein kinase A (PKA).
4. Downstream effects: PKA phosphorylates multiple substrates, leading to smooth muscle relaxation (vasodilation), inhibition of platelet aggregation, and modulation of inflammatory signaling.

In the corpus cavernosum, this signaling cascade results in relaxation of trabecular smooth muscle and dilation of cavernosal arteries, facilitating penile engorgement and erection. In the ductus arteriosus, activation of EP receptors maintains patency of the vessel, which is critical for neonatal survival in certain congenital heart defects.

Comparison with Peptide Therapeutics#

It is important to distinguish alprostadil from peptide-based therapeutics that are discussed elsewhere in this reference. While peptides are linear or cyclic chains of amino acids linked by amide (peptide) bonds, alprostadil is a lipid-derived eicosanoid with a cyclopentane core and no amino acid content. Key differences include:

• Chemical scaffold: Cyclopentane ring with fatty acid chains vs. amino acid polymer
• Molecular weight: 354.48 Da (small molecule range) vs. typical peptides (500-5,000 Da)
• Biosynthesis: COX-mediated oxidation of DGLA vs. ribosomal translation of mRNA
• Metabolism: Enzymatic oxidation (15-PGDH) and beta-oxidation vs. proteolytic cleavage
• Receptor targets: EP prostanoid receptors vs. diverse peptide receptors (GPCRs, kinases, etc.)
• Formulation: Standard small-molecule approaches vs. peptide-specific stability considerations

Despite these fundamental chemical differences, alprostadil is included in this compendium due to its clinical relevance in the same therapeutic areas (vascular function, erectile dysfunction) as several peptide agents, and because it is sometimes encountered alongside peptide therapeutics in clinical and research contexts.

Related Reading#

• Alprostadil overview and research guide
• Peptides similar to Alprostadil
• Alprostadil research evidence